Dr Jasim Uddin
I am a Principal and Market Access Practice Lead in the Health Analytics team, with over 20 years of experience in the biopharmaceutical and allied industries.
As a seasoned market access consultant, I have significant experience in navigating client market access challenges, with a track record of delivery on a range of global market access strategy and communication projects, including manuscript, global value dossier, landscape, payer insight, value story, and other cross-collaborative market access and HEOR projects. I have experience of working with products across a diverse range of therapy areas and a wide range of healthcare product types, including pharmaceuticals, medical devices, diagnostics, and digital prescription therapeutics. I have a specific interest in payer value communications, particularly how to optimally translate evidence into meaningful communications and tools that aim to facilitate optimal patient access.
My previous experience prior to joining the LCP Health Analytics team, includes, senior leadership roles in other market access/HEOR consultancies, where I have led multidisciplinary teams across access, value communications, RWE, HEOR and digital solutions. In addition, I have a wealth of experience working in blue-chip pharmaceutical organizations (AstraZeneca and Novartis) across roles spanning, medical writing, pharmacovigilance, clinical research, medical ethics, medical affairs, market access and expert engagement. This has included around four years in field-based medical and market access liaison roles.
I have a B.Sc. in Pharmacology with Toxicology from King’s College London and received a Ph.D. in Investigative Medicine from Imperial College London, where my postdoctoral research focused on investigating the neuro-immune mechanisms associated with bacterial and parasitic infections.
Featured insights

Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.

Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.

Achieving equitable representation in clinical trials
Matthew Hankins examines how integrating real-world evidence into diversity action plans can help clinical trial sponsors comply with FDA diversity guidance.

Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?
In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.